Cargando…
In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Mayo Foundation for Medical Education and Research
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934692/ https://www.ncbi.nlm.nih.gov/pubmed/33958066 http://dx.doi.org/10.1016/j.mayocp.2021.03.002 |
| _version_ | 1783660864938704896 |
|---|---|
| author | Lavie, Carl J. |
| author_facet | Lavie, Carl J. |
| author_sort | Lavie, Carl J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7934692 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Mayo Foundation for Medical Education and Research |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79346922021-03-05 In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis Lavie, Carl J. Mayo Clin Proc Letter to the Editor Mayo Foundation for Medical Education and Research 2021-05 2021-03-05 /pmc/articles/PMC7934692/ /pubmed/33958066 http://dx.doi.org/10.1016/j.mayocp.2021.03.002 Text en © 2021 Mayo Foundation for Medical Education and Research. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Lavie, Carl J. In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis |
| title | In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis |
| title_full | In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis |
| title_fullStr | In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis |
| title_full_unstemmed | In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis |
| title_short | In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis |
| title_sort | in reply–use of famotidine and risk of severe course of illness in patients with covid-19: a meta-analysis |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934692/ https://www.ncbi.nlm.nih.gov/pubmed/33958066 http://dx.doi.org/10.1016/j.mayocp.2021.03.002 |
| work_keys_str_mv | AT laviecarlj inreplyuseoffamotidineandriskofseverecourseofillnessinpatientswithcovid19ametaanalysis |